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Abstract
Background: Chemoresistance acquisition may influence cancer cell biology. Here, bioinformatics
analysis of gene expression data was used to identify chemoresistance-associated changes in
neuroblastoma biology.
Results: Bioinformatics analysis of gene expression data revealed that expression of angiogenesis-
associated genes significantly differs between chemosensitive and chemoresistant neuroblastoma
cells. A subsequent systematic analysis of a panel of 14 chemosensitive and chemoresistant
neuroblastoma cell lines in vitro and in animal experiments indicated a consistent shift to a more
pro-angiogenic phenotype in chemoresistant neuroblastoma cells. The molecular mechanims
underlying increased pro-angiogenic activity of neuroblastoma cells are individual and differ
between the investigated chemoresistant cell lines. Treatment of animals carrying doxorubicin-
resistant neuroblastoma xenografts with doxorubicin, a cytotoxic drug known to exert anti-
angiogenic activity, resulted in decreased tumour vessel formation and growth indicating
chemoresistance-associated enhanced pro-angiogenic activity to be relevant for tumour
progression and to represent a potential therapeutic target.
Conclusion: A bioinformatics approach allowed to identify a relevant chemoresistance-associated
shift in neuroblastoma cell biology. The chemoresistance-associated enhanced pro-angiogenic
activity observed in neuroblastoma cells is relevant for tumour progression and represents a
potential therapeutic target.
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Neuroblastoma is the most frequent extracranial solid
tumour of childhood. About half of all neuroblastoma
patients are diagnosed with high-risk disease with overall
survival rates below 40% despite intensive multimodal
treatment [1]. Therapy failure is basically caused by
acquired chemoresistance. Primary tumours usually
respond to initial chemotherapy. However, a significant
fraction of tumours reappear as chemoresistant recidives
[2].
Acquisition of chemoresistance under therapy may affect
the biology of neuroblastoma and other tumour cells [3-
9]. Mostly a shift towards a more malignant phenotype is
observed indicating cancer progression [3,4,6-9]. Molecu-
lar changes in different signalling pathways including
apoptosis signalling or cell cycle regulation may be
involved in this coincidence of cancer cell chemoresist-
ance and increased malignancy [3,10,11]. Neuroblastoma
cells adapted to different cytotoxic drugs showed
increased malignant properties as indicated by enhanced
invasive potential in vitro [7,8] and increased malignancy
in nude mice [9].
Here, differences in angiogenesis signalling were identi-
fied by bioinformatics pathway analysis of gene expres-
sion data from chemosensitive and chemoresistant
neuroblastoma cells. Subsequently, cell culture and ani-
mal experiments using 14 human neuroblastoma cell
lines indicated a consistently higher pro-angiogenic activ-
ity of chemoresistant neuroblastoma cells than of chemo-
sensitive cells. The molecular mechanisms underlying the
chemoresistance-associated increased pro-angiogenic
potential were individual and differed between individual
cell lines. Doxorubicin treatment of doxorubicin-resistant
neuroblastoma xenografts resulted in impairment of
tumour angiogenesis and growth suggesting the chemore-
sistance-associated pro-angiogenic phenotype to contrib-
ute to tumour progression.
Methods
Gene expression analysis
Gene expression analysis using AB1700 Human Genome
Survey Microarray V2.0 chips (Applied Biosystems, Darm-
stadt, Germany) was performed by IMGM laboratories
(Martinsried, Germany). Gene expression analysis using
GeneChip HGU133 Plus 2.0 (Affymetrix, Santa Clara, CA,
USA) was performed by Fraunhofer Institut für Zellthera-
pie und Immunologie (Leipzig, Germany). mRNA was
isolated using the RNeasy kit (Qiagen, Hilden, Germany)
according to the manufacturer's instructions. Triplicates of
UKF-NB-3 RNA were compared to triplicates of UKF-NB-
3rVCR10 RNA, UKF-NB-3rDOX20 RNA, or UKF-NB-
3rCDDP1000 RNA.
AB1700 expression data were processed using the R/bio-
conductor package 'ABarray' (http://www.r-project.org/;
http://www.bioconductor.org/) with default parameter
(SN threshold > = 3, % Detect Samples: 0.5). This
included quality control, quantile normalisation [12] and
filtering of unspecific hybridisation. HGU133 Plus 2.0
expression data were processed using the R/bioconductor
packages 'gcrma' and 'limma' (http://www.r-project.org/;
http://www.bioconductor.org/).
For every microarray experiment, the expression pattern of
50 randomly chosen genes was verified by quantitative
real-time PCR resulting in confirmation of expression of
>80% of investigated genes (data not shown).
Signal transduction pathway bioinformatics
Statistical analysis to identify significant expression
changes was focusing on a pathway analysis using the
PANTHER database [13]http://www.pantherdb.org,
which identifies global patterns in expression. For each
expert-curated pathway in the database, potential differ-
ential expression was determined by a binomial test [14],
using the PANTHER human gene reference list matching
our microarrays (Human AB1700 genes) and lists of dif-
ferentially expressed genes that passed a false discovery
rate threshold [15] of 0.05 based on a t-test.
A total of 25,909 genes were annotated in the dataset,
3,125 of them included pathway information, and 223 of
these (corresponding to 280 AB1700 ProbeIDs or 537
HGU133 Plus 2.0 ProbeIDs) were annotated as related to
angiogenesis. For this list of angiogenesis-associated
ProbeIDs and angiogenesis-associated genes signal inten-
sities of UKF-NB-3, UKF-NB-3rVCR10, UKF-NB-
3rCDDP1000, or UKF-NB-3rDOX20 cells were visualised as
heatmaps using R http://www.r-project.org.
Cells
The cell lines UKF-NB-2, UKF-NB-3, and UKF-NB-4 were
isolated from bone marrow metastases from N-myc-
amplified stage 4 neuroblastoma patients [16-18]. Be(2)-
C cells and IMR-32 cells were obtained from ATCC (Man-
assass, VA, USA). Be(2)-C cells and UKF-NB-4 cells were
isolated as chemoresistant cell lines from patients [17].
The parental UKF-NB-2, UKF-NB-3 or IMR-32 cells are
chemosensitive (no P-gp expression, wild-type p53) [19].
Cells were adapted to growth in the presence of vincistine
(10 ng/ml), doxorubicin (20 ng/ml), or cisplatin (1000
ng/ml) as described and named following the published
nomenclature [16-20], e.g. UKF-NB-3rVCR10 means UKF-
NB-3 adapted to vincristine 10 ng/ml, UKF-NB-3rDOX20
means UKF-NB-3 adapted to doxorubicin 20 ng/ml, UKF-
NB-3rCDDP1000 means UKF-NB-3 adapted to cisplatin
1000 ng/ml. P-glycoprotein (P-gp) expression and p53
status are shown in Table 1.Page 2 of 14
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medum (IMDM) supplemented with 10% foetal calf
serum (FCS), 100 IU/ml penicillin, and 100 mg/ml strep-
tomycin at 37°C.
Human umbilical vein endothelial cells (HUVECs) were
cultivated as described before [21] using IMDM supple-
mented with 15% FCS and 5% pooled human serum.
Viability assay
HUVEC viability was investigated using the CellTiter-Glo®
Luminescent Cell Viability Assay (Promega, Mannheim,
Germany) following the manufacturer's instructions.
Caspase activation
Caspase 3/7 activation was measured using the Caspase-
Glo 3/7 Assay (Promega, Mannheim, Germany) following
the manufacturer's instructions.
Tube formation assay
Endothelial cellular tube formation was investigated
using HUVECs seeded on extracellular matrix (Matrigel,
BD Biosciences, Heidelberg, Germany) as described
before [21].
Western blot
Cells were lysed in Triton X-sample buffer and separated
by SDS-PAGE. Proteins were detected using specific anti-
bodies against β-actin (Sigma, Taufkirchen, Germany),
ERK 1/2, the phosphorylated forms of ERK 1/2 (each from
New England Biolabs, Frankfurt am Main, Germany), Akt,
or the phosphorylated forms of Akt (all Millipore
(Upstate), Schwalbach, Germany) and were visualised by
enhanced chemiluminescence using a commercially avail-
able kit (Amersham, Freiburg, Germany).
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assay (EMSA) was per-
formed as described [22].
Animal experiments
Experiments using the chick chorioallantoic membrane
(CAM) were performed using described methods [23].
106 cells were placed onto the CAM at day 8. Vessel forma-
tion was examined at day 12.
Mouse experiments were performed using female
NMRI:nu/nu mice as described before [9]. 107 cells were
injected subcutaneously together with Matrigel in a total
volume of 100 μl. For doxorubicin treatment, the day
when xenograft tumours became palpable was defined to
be day 1. Tumour sections were stained for apoptotic cells
by TUNEL staining and for cell proliferation by ki67 stain-
ing using established methods [24,25].
Table 1: Influence of supernatants from different neuroblastoma cell lines on endothelial cell growth and endothelial cell survival
P-gp1 p53 mutation2 Endothelial cell growth (%)3 Endothelial cell survival (%)4
Positive control5 100 ± 8 100 ± 9
Negative control6 5 ± 7 12 ± 6
UKF-NB-3 - - 15 ± 6 22 ± 8
UKF-NB-3rVCR10 + + (C135F) 78 ± 12* 83 ± 12*
UKF-NB-3rCDDP1000 - - 89 ± 9* 85 ± 7*
UKF-NB-3rDOX20 + - 66 ± 13* 70 ± 6*
UKF-NB-2 - - 17 ± 11 20 ± 5
UKF-NB-2rVCR10 + - 48 ± 13* 55 ± 8*
UKF-NB-2rCDDP1000 - - 38 ± 7* 48 ± 10*
UKF-NB-2rDOX20 + - 35 ± 9* 42 ± 9*
IMR-32 - - 8 ± 6 17 ± 5
IMR-32rVCR10 + - 63 ± 15* 67 ± 8*
IMR-32rCDDP1000 - - 49 ± 7* 58 ± 6*
IMR-32rDOX20 - - 37 ± 8* 44 ± 14*
UKF-NB-4 + + (C175F) 92 ± 9# 78 ± 15#
Be(2)-C + + (C135F) 94 ± 16# 90 ± 7#
1 P-glycoprotein (P-gp) expression; + = overexpression, - = no overexpression
2 p53 status; + = mutated p53, - = wild-type p53
3 endothelial cells were grown in cancer cell culture supernatants mixed 1:1 with IMDM supplemented with 10% FCS; cell number was determined 
after 120 h
4 confluent endothelial cell monolayers were incubated with cancer cell culture supernatants mixed 1:1 with IMDM supplemented with 10% FCS; 
cell number was determined after 48 h
5 IMDM supplemented with 15% FCS, 5% human serum, bFGF 2.5 ng/ml
6 IMDM supplemented with 10% FCS
* P < 0.05 relative to corresponding parental chemosensitive neuroblastoma cell line
# P < 0.05 relative to the parental chmosensitive neuroblastoma cell lines UKF-NB-3, UKF-NB-2, and IMR-32.Page 3 of 14
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mals and with the German Animal Protection Law.
Results
Expression of angiogenesis-associated genes
A pathway analysis was performed in order to detect the
most strongly influenced signalling pathways between
UKF-NB-3 and its chemoresistant sub-lines UKF-NB-
3rVCR10 and UKF-NB-3rCDDP1000. Of the 153 pathways
mapped at PANTHER, angiogenesis was found to be the
fourth most significantly affected signalling pathway (p =
1.87 × 10-4) [see Additional file 1].
Hierarchical cluster analysis and the heatmap indicating
expression of angiogenesis-associated ProbeIDs (Figure 1)
illustrate a striking and consistent re-arrangement of ang-
iogenesis-related gene expression in the resistant cells. The
39 angiogenesis-related ProbeIDs differentially regulated
between UKF-NB-3 and UKF-NB-3rVCR10 cells represent
35 genes [see Additional file 2]. Of these 35 genes, 27 were
up-regulated in UKF-NB-3rVCR10 cells in comparison to
UKF-NB-3 cells and 8 were down-regulated. The 10 angio-
genesis-related ProbeIDs differentially regulated between
UKF-NB-3 and UKF-NB-3rCDDP1000 cells represent 10
genes [see Additional file 3]. Of these 10 genes, 8 were up-
regulated in UKF-NB-3rCDDP1000 cells in comparison to
UKF-NB-3 cells and 2 were down-regulated.
Subsequently to these analyses, we compared angiogen-
esis signalling between UKF-NB-3 and UKF-NB-3rDOX20
cells. Since Applied Biosystems had stopped manufactur-
ing of AB1700 arrays, HGU133 Plus 2.0 arrays (Affyme-
trix) were used. Results were similar to those obtained
from the comparison of UKF-NB-3 with UKF-NB-3rVCR10
and UKF-NB-3rCDDP1000 cells. PANTHER pathway analy-
sis indicated angiogenesis to be the fourth most signifi-
cantly differentially regulated signalling pathway [see
Additional file 4]. Hierarchical cluster analysis of angio-
genesis-associated genes separated UKF-NB-3 from UKF-
Hierarchical cluster analysis and heatmap showing expression of angiogenesis-associatd genes (taken from PANTHER pathway) in UKF-NB-3, UKF-NB-3rVCR10, or UKF-NB-3rCDDP1000 cellsFigure 1
Hierarchical cluster analysis and heatmap showing expression of angiogenesis-associatd genes (taken from 
PANTHER pathway) in UKF-NB-3, UKF-NB-3rVCR10, or UKF-NB-3rCDDP1000 cells. Data were merged from two 
independent exeriments each comparing UKF-NB-3 with one chemoresistant cell line. UKF-NB-3a was analysed together with 
UKF-NB-3rVCR10, UKF-B-3b was analysed together with UKF-NB-3rCDDP1000.
UKF-NB-3aUKF-NB-
3rVCR10
UKF-NB-
3rCDDP1000
Figure 1
UKF-NB-3bPage 4 of 14
(page number not for citation purposes)
Molecular Cancer 2009, 8:80 http://www.molecular-cancer.com/content/8/1/80NB-3rDOX20 cells [see Additional file 5]. 65 angiogenesis-
associated genes were found significantly differentially
regulated between UKF-NB-3 and UKF-NB-3rDOX20 cells.
38 genes were up-regulated in UKF-NB-3rDOX20 cells and
27 genes were down-regulated in UKF-NB-3rDOX20 rela-
tive to UKF-NB-3 cells [see Additional file 6]. The rela-
tively high number of significantly differentially regulated
genes compared to the comparisons of UKF-NB-3 vers.
UKF-NB-3rVCR10 or UKF-NB-3rCDDP1000 cells most likely
results from the different statistical procedures used to
analyse HGU133 Plus 2.0 or AB1700 data.
To further investigate the influence of chemoresistance
acquisition on the pro-angiogenic potential of cancer
cells, a panel of chemsensitive and chemoresistant neu-
roblastoma cell lines was systematically investigated for
their angiogenic phenotypes.
Influence of neuroblastoma cell line supernatants on 
endothelial cell growth and survival
Neuroblastoma cell lines were grown for seven days. Then
medium was removed, cells were washed and protein-free
medium was added. After 48 h incubation, supernatants
were collected, adjusted to the same protein content,
mixed in a 1:1 ratio with fresh IMDM, and FCS (resulting
in 10% FCS) was added (unless otherwise noted, all cell
culture supernatants were handled following this proce-
dure). HUVECs were trypsinised and suspended in the
mixtures of supernatants, fresh IMDM and FCS (without
further addition of growth factors). 103 cells suspended in
100 μl of respective medium were seeded per well in 96-
well plates. After five days, HUVEC growth was examined
by viability assay (Table 1). HUVECs suspended in IMDM
plus 10% FCS did not grow (negative control). HUVECs
suspended in IMDM plus 15% FCS, 5% pooled human
serum, and basic fibroblast growth factor (bFGF) 2.5 ng/
ml formed vital, closely grown monolayers (positive con-
trol). Cell viabilities were calculated relative to positive
control. Supernatants from cell lines adapted to cytotoxic
drugs induced stronger HUVEC growth than supernatants
from parental chemosensitive cells (Table 1). Moreover,
the neuroblastoma cell lines UKF-NB-4 and Be(2)-C that
were isolated as chemoresistant cell lines from patients
materials induced stronger HUVEC growth than the
chemosensitive parental cell lines UKF-NB-3, UKF-NB-2,
or IMR-32. Subsequently, growth kinetics of HUVECs
(determined by cell count) incubated with supernatants
of UKF-NB-3, UKF-NB-3rVCR10, UKF-NB-3rCDDP1000, or
UKF-NB-3rDOX20 cells were compared confirming
increased growth of HUVECs incubated with supernatants
of chemoresistant cells (Figure 2A).
Next, the influence of neuroblastoma cell culture superna-
tants was examined on HUVEC survival. Confluent
HUVEC monolayers were washed and incubated for 48 h
with supernatants of UKF-NB-3, UKF-NB-3rVCR10, UKF-
NB-3rCDDP1000, or UKF-NB-3rDOX20 cells and HUVEC
viability was determined. Results revealed increased
Influence of neuroblastoma cell culture supernatants on endothelial cell growth and viabilityFigure 2
Influence of neuroblastoma cell culture supernatants on endothelial cell growth and viability. A) Cell growth 
characteristics of human umbilical vein endothelial cells (HUVECs) incubated with a mixtures of neuroblastoma cell culture 
supernatants and IMDM (1:1) supplemented with 10% FCS indicated by cell count. B) Caspase 3/7 activation in confluent 
endothelial cell monolayers incubated with a mixtures of neuroblastoma cell culture supernatants and IMDM (1:1) supple-
mented with 10% FCS for 48 h. * P < 0.05 relative to endothelial cells incubated with UKF-NB-3 supernatants.
A  UKF-NB-3 supernatant
 UKF-NB-3rDOX20 supernatant
 UKF-NB-3rVCR10 supernatant
 UKF-NB-3rCDDP1000 supernatant
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of chemoresistant cells (Table 1). Lack of growth factors or
nutrients induces apoptosis in endothelial cells [26-28].
Therefore, we investigated caspase 3/7 activation as indi-
cator of apoptosis in confluent HUVEC monolayers incu-
bated for 48 h with supernatants of UKF-NB-3, UKF-NB-
3rVCR10, UKF-NB-3rCDDP1000 cells or UKF-NB-3rDOX20
cells. Results indicated decreased caspase activation in
HUVECs incubated with supernatants from chemoresist-
ant cells (Figure 2B).
Influence of neuroblastoma cell line supernatants on 
endothelial cell tube formation
HUVECs were suspended with supernatants of neuroblas-
toma cell lines and seeded on extracellular matrix
(Matrigel). After 16 h, tube formation was determined.
Results indicated increased tube formation in HUVECs
suspended in supernatants of UKF-NB-3rVCR10, UKF-NB-
3rCDDP1000, or UKF-NB-3rDOX20 cells in comparison to
HUVECs suspended in supernatants of the parenal chem-
osensitive UKF-NB-3 cell line (Figure 3A, B). Similar
results were detected in the parental cell lines IMR-32 and
UKF-NB-2 in comparison to their chemoresistant sub-
lines [see Additional file 7]. Using different ratios of
supernatants from the cell lines UKF-NB-3rVCR10 or UKF-
NB-3rCDDP1000 and IMDM indicated that the superna-
tants induce tube formation in a concentration-depend-
ent manner [see Additional file 7].
Influence of neuroblastoma cell line supernatants on 
activation of pro-angiogenic signalling events in 
endothelial cells
The phosphoinositide-3-kinase (PI3K) - Akt (also known
as protein kinase B, PKB) signalling pathway, "classical"
mitogen-activated protein kinase (MAPK) signalling via
Ras-Raf-MEK-ERK, and activation of nuclear factor κB
(NFκB) are involved in angiogenesis signalling in
endothelial cells [29-31]. The influence of supernatants of
chemoresistant cells on Akt phosphorylation or ERK 1/2
phosphorylation in HUVECs is shown in Figure 3C. Den-
sitometric analysis of Western blot data is given in Addi-
tional file 8. Akt may be activated through
phosphorylation at Ser473 and/or at Thr308. The super-
natants of UKF-NB-3rVCR10 or UKF-NB-3rCDDP1000 cells
induced enhanced Akt phosphorylation at Thr308 and
ERK 1/2 phosphorylation in comparison to UKF-NB-3
supernatants. All supernatants of chemoresistant cells
caused enhanced NFκB activation relative to supernatants
of chemosensitive UKF-NB-3 cells (Figure 3D).
Chemoresistant cancer cells induce increased vessel 
formation in animal models
Vessel formation was first investigated in vivo in the CAM
of fertilised eggs. 106 tumour cells were seeded onto the
CAM per egg (eight eggs per cell line) at day 10. Vessel for-
mation was scored by two independent observers at day
14. Results indicated higher vessel formation in chemore-
sistant (UKF-NB-3rVCR10, UKF-NB-3rDOX20) cells than in
chemosensitive (UKF-NB-3) cells (Figure 4A).
Vessel formation was further investigated in xenografts
formed of UKF-NB-3, UKF-NB-3rVCR10, or UKF-NB-
3rDOX20 cells in female NMRI:nu/nu mice. Tumour take
in mice injected with UKF-NB-3rVCR10 cells was 100%, in
mice injected with UKF-NB-3rDOX20 cells it was 90%
while only 10% of UKF-NB-3 cell-injected mice formed
tumours. UKF-NB-3rVCR10 cells and UKF-NB-3rDOX20
cells also formed considerably bigger and stronger vascu-
larised xenograft tumours than UKF-NB-3 cells (Figure 4B-
D).
Increased pro-angiogenic activity of chemoresistant 
neuroblastoma cells is mediated by individual molecular 
mechanisms
VEGF is a pro-angiogenic factor that has frequently been
associated with neuroblastoma angiogenesis [32,33].
However, increased VEGF levels were not consistently
found in supernatants of chemoresistant cells [see Addi-
tional file 9]. Acute cisplatin treament has been described
to induce tumour progression through VEGF expression
in paediatric tumour cells including the neuroblastoma
cell line SK-N-BE2 [34]. In cisplatin-resistant neuroblast-
oma cells, VEGF expression has not been investigated, yet.
Increased VEGF levels were detected in UKF-NB-
3rCDDP1000 cells versus UKF-NB-3 cells and in IMR-
32rCDDP1000 cells versus IMR-32 cells but not in UKF-NB-
2rCDDP10 cells versus UKF-NB-2 cells [see Additional file
9]. Moreover, the pro-angiogenic factors interleukin-8 (IL-
8), angiogenin, basic fibroblast growth factor, or tumour
necrosis factor α (TNF-α) were not generally found to be
increased in supernatants of chemoresistant cells [see
Additional file 9]. Two angiogenesis-associated genes
(ARHGAP8, FGFR2) were found commonly up-regulated
in UKF-NB-3rCDDP1000, UKF-NB-3rVCR10, or UKF-NB-
3rDOX20 cells versus UKF-NB-3 cells [see Additional files
2, 3, 6]. However, these genes were not consistently found
up-regulated in chemoresistant neuroblastoma cells (data
not shown).
Expression of a number of further pro- and anti-ang-
iogenic factors has been suggested to be relevant for neu-
roblastoma angiogenesis including platelet-derived
growth factor α (PDGFα), matrix metalloproteinase 2
(MMP-2), MMP-9, erythropoietin (EPO), EPO receptor,
activin A, interleukin-6 (IL-6), leukemia inhibitory factor
(LIF), tissue inhibitor of metalloproteinase 2 (TIMP2),
pigment epithelial-derived growth factor (PEDGF),
secreted protein acidic and rich in cysteine (SPARC),
thrombospondin-1, and thrombospondin-2 [33]. How-
ever, analysis of gene microarray data from neuroblast-Page 6 of 14
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Molecular Cancer 2009, 8:80 http://www.molecular-cancer.com/content/8/1/80oma cell lines did not reveal specific expression of these or
other angiogenesis-related genes that would suggest a sin-
gle common molecular event underlying increased neu-
roblastoma tumour angiogenesis in all chemoresistant
cells (data not shown).
N-myc amplification has also been reported to result in
increased neuroblastoma tumour angiogenesis through
different mechanisms [33,35-37]. However, UKF-NB-
3rDOX20 cells showed enhanced pro-angiogenic potential
compared to UKF-NB-3 cells although both cell lines do
neither differ in N-myc amplification nor in N-myc
expression [8,18]. This indicates that the N-myc status
may not generally be critical for increased pro-angiogenic
potential of chemoresistant cells. Furthermore, the loss of
functional p53 during tumourigenesis has been correlated
to a more pro-angiogenic tumour phenotype [38]. How-
ever, in our experiments pro-angiogenic activity was
enhanced in both p53-mutated and p53-wild-type chem-
oresistant neuroblastoma cells (Table 1). Taken together,
Influence of neuroblastoma cell culture supernatants on tube formation and activation of pro-angiogenic signalling pathways in endothelial cellsFigure 3
Influence of neuroblastoma cell culture supernatants on tube formation and activation of pro-angiogenic sig-
nalling pathways in endothelial cells. A) Representative photographs showing tube formation of human umbilical vein 
endothelial cells (HUVECs) suspended in 1:1 mixtures of IMDM + 10 FCS and supernatants of parental chemosensitive UKF-
NB-3 cells or sublines adapted to vincristine (UKF-NB-3rVCR10), cisplatin (UKF-NB-3rCDDP1000), or doxorubicin (UKF-NB-
3rDOX20) 16 h after seeding on extracellular matrix. B) Quantification of tube formation by counting of branching points of 
HUVEC incubated with 1:1 mixtures of IMDM and supernatants of UKF-NB-3, UKF-NB-3rVCR10, UKF-NB-3rCDDP1000, or 
UKF-NB-3rDOX20 cells + 10% FCS in comparison to endothelial cell medium (EC medium, IMDM + 15% FCS + 5% pooled 
human serum + bFGF 2.5 ng/ml) and growth factor-free medium (GF-free medium, IMDM + 10% FCS). P < 0.05 relative to 
endothelial cells incubated with UKF-NB-3 supernatants. C) Representative Western blot showing expression of ERK 1/2, 
phosphorylated ERK 1/2 (pERK 1/2), Akt, Akt phosphorylated at Ser473 (pAkt Ser473), or Akt phosphorylated at Thr308 
(pAkt Thr308) in endothelial cells incubated with 1:1 mixtures of IMDM and supernatants of UKF-NB-3, UKF-NB-3rVCR10, 
UKF-NB-3rCDDP1000, or UKF-NB-3rDOX20 cells + 10% FCS in comparison to EC medium and GF-free medium for 24 h. β-
actin was used as loading control. D) Representative EMSA showing nuclear factor κB (NFκB) activation in endothelial cells 
incubated with 1:1 mixtures of IMDM and supernatants of UKF-NB-3, UKF-NB-3rVCR10, UKF-NB-3rCDDP1000, or UKF-NB-
3rDOX20 cells + 10% FCS for 24 h. Tumour necrosis factor α (TNFα) was used as positive control.
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Molecular Cancer 2009, 8:80 http://www.molecular-cancer.com/content/8/1/80the more pro-angiogenic phenotype observed in chem-
oresistant neuroblastoma cells appears to result from dif-
ferent individual shifts in the expression of angiogenesis-
associated genes.
Doxorubicin inhibits tumour angiogenesis and growth of 
doxorubicin-resistant neuroblastoma xenografts
Data had indicated individual changes in the expression
of angiogenesis-related genes to be responsible for the
proangiogenic phenotype of chemoresistant neuroblast-
oma cells (see above). To investigate if the increased pro-
angiogenic activity of chemoresistant neuroblastoma cells
may be relevant for enhanced growth of chemoresistant
neuroblastoma xenografts, doxorubicin-resistant UKF-
NB-3rDOX20 neuroblastoma cells were treated with doxo-
rubicin that is known to interfere with angiogenesis by
direct influence on endothelial cells [39,40].
Administration of a single dose of doxorubicin 10 mg/kg
i.v. into mice results in maximal doxorubicin plasma lev-
els in the range of 500 - 600 ng/ml that decline to doxoru-
bicin plasma levels of 20 - 30 ng/ml 24 h after injection
[40-42]. One time application of doxorubicin 8 mg/kg i.v.
resulted in intratumoural doxorubicin concentrations of
about 10 - 20 ng/ml in a melanoma xenograft model [43].
The doxorubicin IC50 values of UKF-NB-3rDOX20 cells are
> 4000 ng/ml after a 24 h incubation period and 180.50
± 22.13 ng/ml after 120 h incubation period. Dose
response curves for doxorubicin treatment of UKF-NB-
3rDOX20 cells are shown in comparison to parental chem-
osensitive UKF-NB-3 cells in Figure 5A. Consequently,
treatment of UKF-NB-3rDOX20 xenograft carrying mice
with doxorubicin 8 mg/kg i.v. should not directly affect
UKF-NB-3rDOX20 cell viability and tumour growth. There-
fore, mice received doxorubicin 8 mg/kg i.v. when
tumours became palpable and tumour volumes were
Vessel formation induced by neuroblastoma cells in vivoFigure 4
Vessel formation induced by neuroblastoma cells in vivo. A) Representative photographs of vessels induced by neurob-
lastoma cell lines in the chick chorioallantoic membrane. B) Growth curves of UKF-NB-3, UKF-NB-3rVCR10, or UKF-NB-
3rDOX20 tumours in nu/nu mice; UKF-NB-3rVCR10 and UKF-NB-3rDOX20 cells formed statistically significant larger tumours 
than UKF-NB-3 cells C) Representative photographs of angiogenesis in UKF-NB-3 or UKF-NB-3rVCR10 xenograft tumours in 
nu/nu mice indicated by red (anti-CD31 antibody-stained) vessels. D) Microvessel density in UKF-NB-3 or UKF-NB-3rVCR10 
xenograft tumours in nu/nu mice. * P < 0.05 relative to UKF-NB-3 tumours.
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Molecular Cancer 2009, 8:80 http://www.molecular-cancer.com/content/8/1/80observed for 16 days. Then mice were sacrificed and
xenograft tumours were examined for vessel density. Dox-
orubicin strongly reduced UKF-NB-3rDOX20 xenograft
growth as well vessel density in the tumours (Figure 5B-
D). TUNEL staining indicated an increase in the number
of apoptotic cells in doxorubicin-treated (231 ± 61 cells
per microscopic field at 200× magnification) vs. non-
treated UKF-NB-3rDOX20 (112 ± 22 cells per microscopic
field at 200× magnification) xenografts. The fraction of
ki67-expressing proliferating cells was higher in non-
treated tumours (163 ± 26 cells per microscopic field at
200× magnification) than in doxorubicin-treated
tumours (101 ± 14% cells per microscopic field at 200×
magnification) indicating decreased proliferation.
Discussion
Here, we used a bioinformatics-based approach based on
transcriptomics data to identify signalling pathways asso-
ciated with increased malignant behaviour of chemore-
sistant neuroblastoma cells. Angiogenesis signalling
belonged to the top 5 pathways most strongly differen-
tially regulated between chemosensitive and chemoresist-
ant neuroblastoma cells. Systematic evaluation of a panel
of neuroblastoma cell lines in cell culture and animal
models showed consitently increased pro-angiogenic
acivity exerted by chemoresistant cells. These findings are
in accordance with previous reports showing that human
melanoma and breast cancer cells selected for resistance to
chemotherapeutic agents produced higher levels of multi-
ple angiogenic factors [44,45]. Moreover, an increased
microvessel density (MVD) was detected in chemotherapy
resistant xenograft tumours [44,45].
Selection of cancer stem cells has been suggested to play a
role in the enhanced pro-angiogenic activity seen in
chemoresistant cancer cells. In lung cancer cells, treatment
Influence of doxorubicin on viability of neuroblastoma cells, growth of doxorubicin-resistant neuroblastoma xenografts, and vess l formati n in doxorubicin-resista t neuroblastoma xenograftsFigure 5
Influence of doxorubicin on viability of neuroblastoma cells, growth of doxorubicin-resistant neuroblastoma 
xenografts, and vessel formation in doxorubicin-resistant neuroblastoma xenografts. A) Dose-response curves of 
parental chemosensitive neuroblastoma cell cultures (UKF-NB-3; black square) or the doxorubicin-resistant sub-line (UKF-NB-
3rDOX20; black dot) after 24 h or 120 h incubation periods. B) Tumour volumes in mice injected with 107 UKF-NB-3rDOX20 
cells; doxorubicin treatment (8 mg/kg i.v.) was performed at day 1, i.e. when tumours became palpable. C) Representative pho-
tographs of angiogenesis in untreated or doxorubicin-treated UKF-NB-3rDOX20 xenograft tumours by red (anti-CD31 anti-
body-stained) vessels at day 16. D) Microvessel density in untreated or doxorubicin-treated UKF-NB-3rDOX20 xenografts at 
day 16. * P < 0.05 relative to UKF-NB-3 tumours.
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Molecular Cancer 2009, 8:80 http://www.molecular-cancer.com/content/8/1/80with cisplatin, doxorubicin, or etoposide resulted in the
selection of cancer stem cells as indicated by cell biology
and analysis of expression of stemness genes [46]. These
chemotherapy-selected cancer stem cells were responsible
for the observed increased pro-angiogenic properties of
lung cancer cells. In the absence of cytotoxic drugs, lung
cancer cell lines returned to their initial phenotype and re-
acquired drug sensitivity [46]. In contrast, UKF-NB-
3rVCR10 and UKF-NB-3rCDDP1000 cells remained chem-
oresistant and did not loose their pro-angiogenic pheno-
type even when they were cultivated for up to six months
in the absence of drugs (data not shown). This suggests
that chemoresistance and pro-angiogenic activity in these
cell lines are not consequence of a simple chemotherapy-
induced selection of cancer stem cells that are already
present in the parental UKF-NB-3 cell line. Moreover,
acute cisplatin treatment increased VEGF expression
together with expression of the stemness genes Nanog,
Bmi-1, and Oct 4 in osteosarcoma (HOS), rhabdomyosa-
rcoma (RH-4) and neuroblastoma (SK-N-BE2) cell lines
[46]. However, none of these stemness genes was found
up-regulated in UKF-NB-3rVCR10 or UKF-NB-3rCDDP1000
cells relative to UKF-NB-3 cells [see Additional file 10].
The finding that cell culture supernatants from chemore-
sistant cells exerted stronger pro-angiogenic effects than
those from chemosensitive cells suggests that soluble fac-
tors contribute to the enhanced pro-angiogenic activity
exerted by chemoresistant neuroblastoma cells. Statistical
analysis of the expression of angiogenesis-related genes
indicated clear differences between chemosensitive UKF-
NB-3 cells and the chemoresistant sub-lines UKF-NB-
3rVCR10, UKF-NB-3rCDDP1000, or UKF-NB-3rDOX20 (Fig-
ure 1) [see Additional files 1, 4, 5]. Obviously, chemore-
sistance development resulted in a global change of
expression of angiogenesis-associated genes towards a
more pro-angiogenic phenotype. The resistance-related
changes in expression patterns appear to differ between
individual chemoresistant neuroblastoma cell lines. This
suggests that the enhanced pro-angiogenic phenotype
observed in all chemoresistant neuroblastoma cell lines in
comparison to the chemosensitive cell lines is caused by
different (individual) changes in the expression patterns
of angiogenesis-associated genes. Notably, hierarchical
clustering of expression of angiogenesis-associated genes
also clearly discriminated UKF-NB-2 cells from UKF-NB-
2rVCR10 and UKF-NB-2rCDDP1000 cells [see Additional
file 11], as well as IMR-32 cells from IMR-32rVCR10 cells
[see Additional file 12].
The view that individual chemoresistant neuroblastoma
cell lines exert pro-angiogenic effects by individual mech-
anisms is supported by the results derived from the exam-
ination of pro-angiogenic signalling in endothelial cells
incubated with supernatants from different neuroblast-
oma cell lines. Supernatants of chemoresistant UKF-NB-
3rDOX20, UKF-NB-3rVCR10, and UKF-NB-3rCDDP1000
cells enhanced NFκB activation compared to supernatants
of chemosensitive UKF-NB-3 cells However, only super-
natants of UKF-NB-3rVCR10 and UKF-NB-3rCDDP1000
cells but not UKF-NB-3rDOX20 cells elevated Akt and ERK
1/2 phosphorylation in endothelial cells. Based on these
differences in the activation of pro-angiogenic signalling
events in endothelial cells, it appears plausible that
endothelial cell activation might be caused by different
chemoresistant neuroblastoma cell lines by different
molecular mechanisms resulting in up- or down-regula-
tion of varying pro- or anti-angiogenic factors.
Possibly, there is an overlap between gene products
involved in angiogenesis and gene products relevant in
chemoresistance. Indeed, among between the aniogen-
esis-associated genes that were differentially expressed
there are those that are also considered to contribute to
chemoresistance. Three arbitrarily chosen examples are
BIRC5, MAPK3, and AKT1. BIRC5 (increased expression
in UKF-NB-3rVCR10 vs. UKF-NB-3, [see Additional file 2],
and in UKF-NB-3rDOX20 vers. UKF-NB-3, [see Additional
file 6]) encodes for a protein that is also named survivin
and plays a prominent role in apoptosis inhibition and
cancer cell chemoresistance [47]. Moreover, BIRC5
expression in cancer cells has been linked to tumour ang-
iogenesis [48] and inhibition of BIRC5 expression in
tumour cells decreased tumour angiogenesis [49,50].
MAPK3 (increased expression in UKF-NB-3rVCR10 vs.
UKF-NB-3, [see Additional file 2]) encodes for a protein
that is also called extracellular signal-regulated kinase 1
(ERK1) and is a constituent of the "classical" MAP kinase
pathway Ras/Raf/MEK/ERK. ERK1 phosphorylation pro-
tects cancer cells from different entities against chemo-
therapy-induced apoptosis [51-53]. Moreover, MAPK3
activation/phosphorylation induces production of pro-
angiogenic factors in renal carcinoma cells [54]. AKT1
(increased expression in UKF-NB-3rDOX20 vers. UKF-NB-
3, [see additional file 6]) encodes for a protein also called
protein kinase B (PKB) that is a central mediator of sur-
vival signals transduced by the phosphatidylinositol 3-
kinase and is involved in chemoresistance [55-57] as well
as in cancer cell expression of pro-angiogenic factors [58-
60]. Remarkably, an angiogenesis-associated gene expres-
sion signature had been described before to predict the
sensitivity of cancer cells to artemisinins, an anti-cancer
active group of anti-malaria drugs [61].
The complexicity of pro-angiogenic mechanisms observed
in chemoresistant neuroblastoma cells is in accordance
with other reports demonstrating that pro-angiogenic
activity of cancer cells is commonly caused by complex
changes in angiogenesis signalling and that inhibition of
one pro-angiogenic event may not be enough to interferePage 10 of 14
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roblastoma cells that exert pro-angiogenic activity mainly
through VEGF have very recently been shown to rapidly
develop alternative pro-angiogenic mechanisms when
VEGF signalling is inhibited [63]. In addition, up-regula-
tion of multiple pro-angiogenic factors enabled carci-
noma cells to escape from angiogenesis inhibition by the
three endogenous anti-angiogenic molecules throm-
bospondin-1, endostatin, and tumstatin [64]. Notably,
combination therapy of metastatic breast cancer with
paclitaxel and the anti-VEGF-A antibody bevacizumab
resulted in prolonged progression-free survival but did
not influence overall survival relative to paclitaxel in a
phase III trial [65]. In the light of the findings presented
here, one may speculate that anti-angiogenic therapy may
prolong progression-free survival but that resistance
development (to chemotherapy and/or anti-angiogenic
therapy) may result in a more aggressive cancer cell phe-
notype, which might be the reason for the decreased time
period observed between tumour re-onset and patients'
deaths.
High tumour angiogenesis and high-level expression of
pro-angiogenic factors at diagnosis have previously been
suggested to be correlated with advanced disease stages in
neuroblastoma [32,66,67]. However, the prognostic value
of angiogenesis in neuroblastoma at diagnosis is still a
matter of debate [68,69]. Notably, analysis of two differ-
ent data sets reporting on gene expression profiles in
tumours from poor outcome or bad outcome N-myc
amplified [70] or non-N-myc amplified [71] neuroblast-
oma patients indicated statistically significant differences
in angiogenesis signalling between these groups [see
Additional files 13, 14]. To investigate if the increased pro-
angiogenic phenotype observed in chemoresistant cells
may contribute to tumour progression, xenografts grown
from doxorubicin-resistant (UKF-NB-3rDOX20) cells were
treated with doxorubicin, an anti-cancer drug that exerts
anti-angiogenic activity by direct effect on endothelial
cells [39,40]. Tumour vessel formation and growth were
strongly reduced by doxorubicin in doxorubicin-resistant
xenografts. Although it cannot be concluded without a
doubt that the entire effect on xenograft growth can be
attributed to inhibition of angiogenesis, microvessel den-
sity was statistically reduced supporting the view that inhi-
bition of angiogenesis has definitely contributed.
Therefore, these data suggest that increased pro-ang-
iogenic activity of doxorubicin-resistant cells contributes
to their more malignant phenotype and that anti-ang-
iogenic strategies that target endothelial cells might repre-
sent a therapeutic option for neuroblastoma treatment.
Conclusion
Bioinformatics pathway analysis indicated differences in
the expression of angiogenesis-associated genes between
chemosensitive and chemoresistant neuroblastoma cell
lines. Cell culture and animal data showed that acquired
resistance to different anti-cancer drugs resulted in
increased pro-angiogenic activity of neurobastoma cells.
The changes in angiogenesis signalling observed in chem-
oresistant neuroblastoma cells are very complex and differ
between individual cell lines. Therefore, individual
molecular mechanisms appear to be responsible for the
enhanced pro-angiogenic activity that was consistently
observed in all investigated chemoresistant neuroblast-
oma cell lines relative to chemosensitive cells. Doxoru-
bicin treatment of doxorubicin-resistant neuroblastoma
xenografts resulted in decreased vessel formation and
tumour growth suggesting that the more pro-angiogenic
phenotype of chemoresistant cells may contribute to
increased malignancy of chemoresistant neuroblastoma
cells and that endothelial cell targeting may represent a
possibility for therapeutic intervention. The complex
nature of the chemoresistance-associated changes respon-
sible for the more pro-angiogenic phenotype strongly
stresses the need for an improved understanding of bio-
logical processes like angiogenesis on a systems biology
level.
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